hotspot -WSS

hotspot

author：leisure time 2025-08-11 09:49:12 - browse：85

Telehealth menopause treatment options displayed on cellphones emerging from a crack in the ground. -- health tech coverage from STAT — Molly Ferguson for STAT

At the turn of the century, nearly 18 million women in the United States were battling hot flashes, night sweats, and other symptoms of menopause with hormones. But in 2002, the therapy went into a free-fall when a landmark trial suggested treating menopause with estrogen and progesterone increased the risk of breast cancer and cardiovascular disease. The study was shut down early — and a year later, prescriptions had plummeted to nearly half what they had been in 2001.

More than two decades later, menopause experts have come to think about the results of the trial very differently. Newer research points to more benefits than risks for many healthy women under 60 treating menopause symptoms with hormone therapy. But many women who are good fits still aren’t getting treatment. “The pendulum has been slowly — too slowly — swinging back,” said OB-GYN Mike Green, chief medical officer of menopause telehealth company Winona.

Winona is part of a new generation of virtual-first health care companies aiming to give that pendulum a push. In the last five years, more than a dozen telehealth companies have started up to serve women in and approaching menopause, including with hormone therapy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Emergency medicine has repudiated 'excited delirium.' Now what?

focus

WSS

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Parkland mass shooting to be reenacted for lawsuit

Eli Lilly to pay $200M for Beam’s stake in gene

Eat, drink, but be wary — 4 foods that interact with medications

Parkland mass shooting to be reenacted for lawsuit

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

hotspot

hotspot

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

Readout Newsletter: What happened with Sarepta's Duchenne data

Heart attack and stroke risk calculators need revising

The pink breast cancer awareness ribbon needs a redesign

Peter Hotez and the public health issue of online harassment

Tuesday set an unofficial record for the hottest day on Earth. Wednesday may break it.

Medicare details structure of new drug price negotiation program

Jesse Tyler Ferguson makes friendship bracelets for Taylor Swift's Eras Tour

The cancer drug shortage isn’t new — and neither are the solutions

FDA has safety concerns on CRISPR

leisure time

'Cuddling' is just what the doctor ordered for a 200

Teen charged with murder as hate crime in killing of NYC dancer O'Shae Sibley: Sources

Emergency medicine has repudiated 'excited delirium.' Now what?

Emergency medicine has repudiated 'excited delirium.' Now what?

Pope greeted like rockstar, appears revitalized at 'Catholic Woodstock' in Portugal

Paying for Covid pills will soon shift to insurers

focus

focus

hotspot

knowledge